FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid TumorsLeigh Marcus, Steven J. Lemery, Reena Philip et al.|Clinical Cancer Research|2021Cited by 567
Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum DiscussionRajeshwari Sridhara, Cindy Lu, Olga Marchenko et al.|Statistics in Biopharmaceutical Research|2021Cited by 35
Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum DiscussionRajeshwari Sridhara, Bruce Binkowitz, Olga Marchenko et al.|Statistics in Biopharmaceutical Research|2021Cited by 12